A 2-week Trial Of PF-04991532 In Patients With Type 2 Diabetes

Back to Search
Print
Bookmark Trial

NCT01469065

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Chula Vista, California, 91911, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Type 2 Diabetes Mellitus
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-70 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients with type 2 diabetes mellitus who are taking either no medication for the treatment of diabetes (diet/exercise therapy only), or who are taking only a single oral anti-diabetic drug (OAD) that can be temporarily discontinued for approximately 8-10 weeks. For those taking a single OAD, treatment should be stable, where this is defined as no change in the treatment, including dose, over the past 3 months prior to Screening. OAD medications that are acceptable to be discontinued include: a sulfonylurea (SU), a meglitinide, a biguanide (eg, metformin), a dipeptidyl peptidase 4 inhibitor (DPP-4i), or an alpha glucosidase inhibitor.

- Body Mass Index (BMI) of 18.5 to 45.0 kg/m2; and a total body weight >50 kg (110 lbs).

- HbA1c >/=7% and /=6.5% and

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Evidence or history of diabetic complications with significant end organ damage.


- History of stroke or transient ischemic attack.


- History of myocardial infarction.


- History of coronary artery bypass graft or stent implantation.


- Clinically significant peripheral vascular disease.


- Any history or clinical evidence of congestive heart failure, NYHA Classes II IV.


- Current history of angina/unstable angina.


- One or more episodes of hypoglycemia within the last 3 months, or two or more episodes
of hypoglycemia within the last 6 months.


- A positive urine drug screen.


- Use of tobacco or nicotine-containing products in excess of the equivalent of 10
cigarettes per day.


- Blood pressure >/=160 mm Hg (systolic) or >/=100 mm Hg (diastolic), following at least
5 minutes of rest.


- Pregnant or nursing females; females of childbearing potential.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Type 2 Diabetes MellitusA Phase 1 Single/Multiple Dose Study Of PF-06293620 To Assess Safety, Tolerability And Pharmacokinetics In Subjects With Type 2 Diabetes Mellitus NCT02211261
  1. Chula Vista, California
  2. Chula Vista, California
  3. DeLand, Florida
  4. Orlando, Florida
  5. South Miami, Florida
  6. South Miami, Florida
  7. High Point, North Carolina
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Type 2 Diabetes MellitusEffect of PF-00734200 in Subjects With Type 2 Diabetes NCT00618007
  1. Birmingham, Alabama
  2. Chandler, Arizona
  3. Litchfield Park, Arizona
  4. Phoenix, Arizona
  5. Artesia, California
  6. Cerritos, California
  7. Fresno, California
  8. Greenbrea, California
  9. Huntington Beach, California
  10. Los Angeles, California
  11. National City, California
  12. Roseville, California
  13. Valley Village, California
  14. West Covina, California
  15. DeFuniak Springs, Florida
  16. Jacksonville, Florida
  17. Miami, Florida
  18. Miami, Florida
  19. New Port Richey, Florida
  20. Ocala, Florida
  21. Pinecrest, Florida
  22. St. Petersburg, Florida
  23. Conyers, Georgia
  24. Idaho Falls, Idaho
  25. Indianapolis, Indiana
  26. Wichita, Kansas
  27. Lexington, Kentucky
  28. Madisonville, Kentucky
  29. Scarborough, Maine
  30. Baltimore, Maryland
  31. Oxon Hill, Maryland
  32. Ann Arbor, Michigan
  33. Bay City, Michigan
  34. Canton, Michigan
  35. Troy, Michigan
  36. Jackson, Mississippi
  37. Picayune, Mississippi
  38. St. Louis, Missouri
  39. St. Louis, Missouri
  40. St. Peters, Missouri
  41. Las Vegas, Nevada
  42. Elizabeth, New Jersey
  43. Trenton, New Jersey
  44. Albuquerque, New Mexico
  45. Syracuse, New York
  46. Winston-Salem, North Carolina
  47. Marion, Ohio
  48. Eugene, Oregon
  49. Cumberland, Rhode Island
  50. Aiken, South Carolina
  51. Florence, South Carolina
  52. Kingsport, Tennessee
  53. Dallas, Texas
  54. Dallas, Texas
  55. El Paso, Texas
  56. Houston, Texas
  57. Houston, Texas
  58. Hurst, Texas
  59. Odessa, Texas
  60. Pearland, Texas
  61. San Antonio, Texas
  62. Salt Lake City, Utah
  63. Bennington, Vermont
  64. Ettrick, Virginia
  65. Richmond, Virginia
  66. Virginia Beach, Virginia
  67. Virginia Beach, Virginia
  68. Spokane, Washington
  69. Kenosha, Wisconsin
  70. Coquitlam, British Columbia
  71. Toronto, Ontario
  72. Laval, Quebec
  73. Pointe-Claire, Quebec
  74. Quebec,
  75. Seoul,
  76. Seoul,
  77. Seoul,
  78. Seoul,
  79. San Juan,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Type 2 Diabetes MellitusThis Study Is To Determine If Inhaled Insulin Is Effective In Treating Type 2 Diabetes Mellitus NCT00418522
  1. Phoenix, Arizona
  2. Tucson, Arizona
  3. Concord, California
  4. Encino, California
  5. Fresno, California
  6. Fullerton, California
  7. Long Beach, California
  8. Mission Viejo, California
  9. Pasadena, California
  10. San Diego, California
  11. San Diego, California
  12. San Luis Obispo, California
  13. Spring Valley, California
  14. Stockton, California
  15. Walnut Creek, California
  16. West Hills, California
  17. Golden, Colorado
  18. Waterbury, Connecticut
  19. Newark, Delaware
  20. Chiefland, Florida
  21. Clearwater, Florida
  22. Hollywood, Florida
  23. Kissimmee, Florida
  24. Miami, Florida
  25. Ocala, Florida
  26. Saint Cloud, Florida
  27. Winter Park, Florida
  28. Atlanta, Georgia
  29. Lawrenceville, Georgia
  30. Lawrenceville, Georgia
  31. Woodstock, Georgia
  32. Boise, Idaho
  33. Hayden Lake, Idaho
  34. Indianapolis, Indiana
  35. Overland Park, Kansas
  36. Topeka, Kansas
  37. Lexington, Kentucky
  38. Louisville, Kentucky
  39. Baton Rouge, Louisiana
  40. New Orleans, Louisiana
  41. Haverhill, Massachusetts
  42. Springfield, Missouri
  43. Omaha, Nebraska
  44. Las Vegas, Nevada
  45. Staten Island, New York
  46. Charlotte, North Carolina
  47. Statesville, North Carolina
  48. Winston-Salem, North Carolina
  49. Kettering, Ohio
  50. Maumee, Ohio
  51. Toledo, Ohio
  52. Oklahoma City, Oklahoma
  53. Medford, Oregon
  54. Melrose Park, Pennsylvania
  55. Greenville, South Carolina
  56. Greer, South Carolina
  57. Spartanburg, South Carolina
  58. Milan, Tennessee
  59. Arlington, Texas
  60. Beaumont, Texas
  61. Dallas, Texas
  62. Dallas, Texas
  63. Dallas, Texas
  64. El Paso, Texas
  65. Houston, Texas
  66. Houston, Texas
  67. San Antonio, Texas
  68. San Antonio, Texas
  69. Bennington, Vermont
  70. Richmond, Virginia
  71. Federal Way, Washington
  72. Menomonee Falls, Wisconsin
  73. Carolina,
ALL GENDERS
30 Years+
years
MULTIPLE SITES
Type 2 Diabetes MellitusSix Month Clinical Trial Assessing Efficacy And Safety Of Inhaled Insulin In Type 2 Diabetes NCT00424411
  1. Burlingame, California
  2. Irvine, California
  3. Los Angeles, California
  4. Newport Beach, California
  5. Orange, California
  6. San Diego, California
  7. San Francisco, California
  8. Tustin, California
  9. New Haven, Connecticut
  10. Washington, District of Columbia
  11. Clearwater, Florida
  12. Miami, Florida
  13. Tampa, Florida
  14. Chicago, Illinois
  15. Louisville, Kentucky
  16. New Orleans, Louisiana
  17. Columbia, Missouri
  18. St Louis, Missouri
  19. St. Louis, Missouri
  20. Omaha, Nebraska
  21. New Hyde Park, New York
  22. New York, New York
  23. Rochester, New York
  24. Durham, North Carolina
  25. Greenville, North Carolina
  26. Winston-salem, North Carolina
  27. Cleveland, Ohio
  28. Portland, Oregon
  29. Austin, Texas
  30. Dallas, Texas
  31. Irving, Texas
  32. San Antonio, Texas
  33. Burlington, Vermont
  34. Charlottesville, Virginia
  35. Renton, Washington
  36. Calgary, Alberta
  37. Edmonton, Alberta
  38. Red Deer, Alberta
  39. Winnipeg, Manitoba
  40. St John's, Newfoundland and Labrador
  41. Halifax, Nova Scotia
  42. Mississauga, Ontario
  43. Ottawa, Ontario
  44. Toronto, Ontario
  45. Chomedy, Quebec
  46. Montreal, Quebec
ALL GENDERS
35 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A 2-week Trial Of PF-04991532 In Patients With Type 2 Diabetes
Official Title  ICMJE A 2-week, Phase 1, Placebo-Controlled, Parallel Group Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Multiple Oral Doses Of PF-04991532 Given As Monotherapy To Adult Patients With Type 2 Diabetes Mellitus
Brief Summary This will be a 2-week oral dose study of PF 04991532, performed in patients with type 2 diabetes. Safety, pharmacokinetics (how the drug is distributed in the body), and pharmacodynamics (how the drug works in the body) will be studied. Patients may be asked to wash off their diabetes medication for 4-6 prior to study drug administration, and they will remain in the clinical research unit for a total of 20 days for baseline tests, 2 weeks of dosing, and some follow up tests.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Condition  ICMJE Diabetes Mellitus, Type 2
Intervention  ICMJE
  • Drug: PF-04991532
    Oral administration of PF-04991532; 25 mg given twice a day (BID) for 14 days
  • Drug: PF-04991532
    Oral administration of PF-04991532; 75 mg given twice a day (BID) for 14 days
  • Drug: PF-04991532
    Oral administration of PF-04991532; 150 mg given twice a day (BID) for 14 days
  • Drug: PF-0499132
    Oral administration of PF-04991532; 300 mg given twice a day (BID) for 14 days
  • Drug: Placebo
    Oral administration of PF-04991532 Matching Placebo; given twice a day (BID) for 14 days
Study Arms  ICMJE
  • Experimental: PF-04991532
    PF-04991532 experimental study medication
    Interventions:
    • Drug: PF-04991532
    • Drug: PF-04991532
    • Drug: PF-04991532
    • Drug: PF-0499132
  • Placebo Comparator: Placebo
    PF-04991532 Matching Placebo
    Intervention: Drug: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: June 26, 2012)		82
Original Estimated Enrollment  ICMJE
 (submitted: November 7, 2011)		80
Actual Study Completion Date  ICMJE May 2012
Actual Primary Completion Date May 2012   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Patients with type 2 diabetes mellitus who are taking either no medication for the treatment of diabetes (diet/exercise therapy only), or who are taking only a single oral anti-diabetic drug (OAD) that can be temporarily discontinued for approximately 8-10 weeks. For those taking a single OAD, treatment should be stable, where this is defined as no change in the treatment, including dose, over the past 3 months prior to Screening. OAD medications that are acceptable to be discontinued include: a sulfonylurea (SU), a meglitinide, a biguanide (eg, metformin), a dipeptidyl peptidase 4 inhibitor (DPP-4i), or an alpha glucosidase inhibitor.
  • Body Mass Index (BMI) of 18.5 to 45.0 kg/m2; and a total body weight >50 kg (110 lbs).
  • HbA1c >/=7% and </=10% if the patient is on diet/exercise therapy only and does not require any OAD discontinuation. HbA1c >/=6.5% and </=9% if the patient requires to be washed off an OAD.

Exclusion Criteria:

  • Evidence or history of diabetic complications with significant end organ damage.
  • History of stroke or transient ischemic attack.
  • History of myocardial infarction.
  • History of coronary artery bypass graft or stent implantation.
  • Clinically significant peripheral vascular disease.
  • Any history or clinical evidence of congestive heart failure, NYHA Classes II IV.
  • Current history of angina/unstable angina.
  • One or more episodes of hypoglycemia within the last 3 months, or two or more episodes of hypoglycemia within the last 6 months.
  • A positive urine drug screen.
  • Use of tobacco or nicotine-containing products in excess of the equivalent of 10 cigarettes per day.
  • Blood pressure >/=160 mm Hg (systolic) or >/=100 mm Hg (diastolic), following at least 5 minutes of rest.
  • Pregnant or nursing females; females of childbearing potential.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 70 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Japan,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01469065
Other Study ID Numbers  ICMJE B2611005
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date September 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP